Want to see HK:1801 full AI Analyst Report?
Innovent Biologics (1801) Ratios
Innovent Biologics Ratios
HK:1801's free cash flow for Q2 2026 was $3.57B. For the 2026 fiscal year, HK:1801's free cash flow was decreased by $-169.65M and operating cash flow was $3.74B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.62 | 2.35 | 3.00 | 3.29 | 3.79 |
| Quick Ratio | 2.47 | 2.16 | 2.78 | 2.88 | 3.35 |
| Cash Ratio | 2.07 | 1.72 | 2.25 | 0.29 | 0.45 |
| Solvency Ratio | 0.08 | 0.02 | -0.08 | -0.27 | -0.43 |
| Operating Cash Flow Ratio | 1.19 | 0.29 | 0.03 | -0.55 | -0.66 |
| Short-Term Operating Cash Flow Coverage | 12.49 | 3.18 | 0.12 | -2.16 | -5.55 |
| Net Current Asset Value | $ 4.82B | $ 1.79B | $ 5.33B | $ 4.65B | $ 5.64B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.13 | 0.18 | 0.18 | 0.15 |
| Debt-to-Equity Ratio | 0.15 | 0.22 | 0.29 | 0.30 | 0.24 |
| Debt-to-Capital Ratio | 0.13 | 0.18 | 0.22 | 0.23 | 0.19 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.16 | 0.16 | 0.17 | 0.16 |
| Financial Leverage Ratio | 1.93 | 1.65 | 1.65 | 1.64 | 1.57 |
| Debt Service Coverage Ratio | 1.49 | -1.05 | -0.42 | -1.78 | -5.76 |
| Interest Coverage Ratio | 9.46 | -11.17 | -17.03 | -30.71 | -43.28 |
| Debt to Market Cap | 0.02 | 0.05 | 0.06 | 0.07 | 0.04 |
| Interest Debt Per Share | 1.67 | 1.78 | 2.38 | 2.23 | 1.76 |
| Net Debt to EBITDA | -10.89 | 9.74 | 9.73 | -1.26 | -0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 76.66% | 83.97% | 70.89% | 79.57% | 86.58% |
| EBIT Margin | 5.63% | -8.02% | -16.85% | -45.40% | -60.41% |
| EBITDA Margin | 10.24% | -5.10% | -10.65% | -38.39% | -55.61% |
| Operating Profit Margin | 5.63% | -8.02% | -27.06% | -68.54% | -63.31% |
| Pretax Profit Margin | 6.43% | -0.83% | -18.44% | -47.64% | -61.87% |
| Net Profit Margin | 6.24% | -1.00% | -16.56% | -47.83% | -63.91% |
| Continuous Operations Profit Margin | 6.24% | -1.00% | -16.56% | -47.83% | -63.91% |
| Net Income Per EBT | 96.98% | 120.36% | 89.82% | 100.41% | 103.29% |
| EBT Per EBIT | 114.35% | 10.40% | 68.15% | 69.50% | 97.72% |
| Return on Assets (ROA) | 2.18% | -0.44% | -4.98% | -12.39% | -16.80% |
| Return on Equity (ROE) | 4.20% | -0.72% | -8.21% | -20.31% | -26.41% |
| Return on Capital Employed (ROCE) | 2.53% | -4.39% | -10.40% | -22.16% | -20.49% |
| Return on Invested Capital (ROIC) | 2.39% | -4.28% | -8.68% | -20.81% | -19.91% |
| Return on Tangible Assets | 2.27% | -0.47% | -4.99% | -13.30% | -17.64% |
| Earnings Yield | 0.69% | -0.17% | -1.70% | -4.94% | -4.78% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.44 | 6.01 | 6.17 | 5.00 | 3.61 |
| Payables Turnover | 6.15 | 4.22 | 4.85 | 2.86 | 2.94 |
| Inventory Turnover | 2.34 | 1.84 | 1.87 | 0.65 | 0.43 |
| Fixed Asset Turnover | 2.40 | 1.67 | 1.33 | 1.12 | 1.26 |
| Asset Turnover | 0.35 | 0.44 | 0.30 | 0.26 | 0.26 |
| Working Capital Turnover Ratio | 1.34 | 1.27 | 0.73 | 0.55 | 0.52 |
| Cash Conversion Cycle | 145.86 | 172.96 | 179.46 | 505.58 | 834.91 |
| Days of Sales Outstanding | 49.03 | 60.70 | 59.16 | 73.04 | 101.02 |
| Days of Inventory Outstanding | 156.17 | 198.71 | 195.56 | 560.20 | 858.13 |
| Days of Payables Outstanding | 59.33 | 86.45 | 75.26 | 127.66 | 124.24 |
| Operating Cycle | 205.20 | 259.41 | 254.72 | 633.24 | 959.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.78 | 0.79 | 0.09 | -1.29 | -1.40 |
| Free Cash Flow Per Share | 5.38 | -0.26 | -0.79 | -2.21 | -2.67 |
| Dividend Paid and CapEx Coverage Ratio | 14.64 | 0.75 | 0.11 | -1.39 | -1.10 |
| Capital Expenditure Coverage Ratio | 14.64 | 0.75 | 0.11 | -1.39 | -1.10 |
| Operating Cash Flow Coverage Ratio | 3.55 | 0.45 | 0.04 | -0.59 | -0.81 |
| Operating Cash Flow to Sales Ratio | 0.77 | 0.14 | 0.02 | -0.42 | -0.47 |
| Free Cash Flow Yield | 7.86% | -0.75% | -2.05% | -7.49% | -6.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 142.68 | -591.18 | -58.77 | -20.23 | -20.90 |
| Price-to-Sales (P/S) Ratio | 9.09 | 5.94 | 9.73 | 9.67 | 13.36 |
| Price-to-Book (P/B) Ratio | 6.12 | 4.26 | 4.82 | 4.11 | 5.52 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 12.72 | -133.71 | -48.89 | -13.35 | -14.73 |
| Price-to-Operating Cash Flow Ratio | 11.85 | 43.47 | 408.73 | -22.97 | -28.17 |
| Price-to-Earnings Growth (PEG) Ratio | -0.15 | 6.48 | 1.07 | 0.91 | -0.14 |
| Enterprise Value Multiple | 77.92 | -106.74 | -81.71 | -26.46 | -24.50 |
| Enterprise Value | 104.02B | 51.27B | 53.98B | 46.29B | 58.17B |
| EV to EBITDA | 77.92 | -106.74 | -81.71 | -26.46 | -24.50 |
| EV to Sales | 7.98 | 5.44 | 8.70 | 10.16 | 13.62 |
| EV to Free Cash Flow | 11.16 | -122.53 | -43.69 | -14.03 | -15.02 |
| EV to Operating Cash Flow | 10.40 | 39.83 | 365.21 | -24.12 | -28.73 |
| Tangible Book Value Per Share | 10.76 | 7.27 | 8.01 | 6.40 | 6.59 |
| Shareholders’ Equity Per Share | 11.19 | 8.06 | 8.03 | 7.20 | 7.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | -0.20 | 0.10 | -0.00 | -0.03 |
| Revenue Per Share | 7.53 | 5.79 | 3.98 | 3.06 | 2.94 |
| Net Income Per Share | 0.47 | -0.06 | -0.66 | -1.46 | -1.88 |
| Tax Burden | 0.97 | 1.20 | 0.90 | 1.00 | 1.03 |
| Interest Burden | 1.14 | 0.10 | 1.09 | 1.05 | 1.02 |
| Research & Development to Revenue | 0.20 | 0.28 | 0.36 | 0.63 | 0.58 |
| SG&A to Revenue | 0.51 | 0.54 | 0.12 | 0.18 | 0.21 |
| Stock-Based Compensation to Revenue | 0.05 | 0.06 | 0.09 | 0.10 | 0.12 |
| Income Quality | 11.92 | -16.37 | -0.13 | 0.88 | 0.74 |
Currency in CNY
